Curium, a world leader in nuclear medicine, has received marketing authorization from the European Commission for its product PYLCLARI™. This radiopharmaceutical is used for the detection of prostate-specific membrane antigen (PSMA) positive lesions in adults with prostate cancer. The approval follows a positive recommendation from The Committee for Medicinal Products for Human Use of the European Medicines Agency. Curium currently has the widest network of PET products production sites in Europe. Prostate cancer is one of the most frequently diagnosed cancers in men in Europe, and PYLCLARI™ will soon be available across Europe to benefit patients. In the US, Curium licensed the European rights for [18F]-DCFPyL, now known as PYLARIFY®, from Lantheus.
Fri, 28 Jul 2023 10:12:30 GMT | GlobeNewswire